Patent Infringement Litigation: How Early Can It Begin?
In a Surprise Decision, FDA Further Delays Approval of Lilly's RA Drug
Senate Bill Seeks to Improve Access to Affordable Rx Drugs
Humira Not Cost Effective for RA, ICER Report Concludes
Study Evaluates Budget Impact of Filgrastim and Similar Biologics for Treating Neutropenia
Sandoz Brief Addresses US Supreme Court in Case Against Amgen
Nominee for FDA Commissioner Vows to Strike Balance Before Senate Panel
Biologics Superior for Relief of IBD Symptoms and Maintenance of Intestinal Health
Indian Generic Pharma Companies in a Race to Develop Biosimilars
MS Drugs Price Comparison Called "Misleading and Oversimplified"
Rituxan Given Breakthrough Therapy Designation for Pemphigus Vulgaris
New Drug Approved for MS, First With PPMS Indication
Dupilumab, a Biologic Treatment for Eczema, Approved by FDA
NHS May Use More "Stick" Than "Carrot" to Ensure Prescribing of Cheaper Biosimilars
Policy Briefing Calls for More Efficient Biosimilar Approval Process
New Lawsuit Concerning Insulin Price-Fixing Filed in Federal Court
Amgen Files for EU Approval of Its Herceptin Biosimilar for Breast Cancer
Congressional Hearing on FDA User Fees Tackles Issues Affecting Biosimilar Approvals
Trump Administration Budget Blueprint Comes With Major Cuts to Health and Science
Greater Transparency at FDA Would Bring More Biosimilars to Market, Experts Say
European Industry Groups Urge Caution on Biosimilar Switching
Amgen Lawsuit Against Coherus Alleges Misappropriation of Neulasta Trade Secrets
Siliq Approved Without a Suffix
New Delhi High Court Allows Marketing of Biocon-Mylan Biosimilar of Trastuzumab
FDA's Director of Drug Evaluation Urges Congress to Pass the BsUFA Reauthorization
US and EU Agree on Mutual Recognition of Drug Manufacturing Inspections
Targeted Regenerative Meds Hold Promise for RA Patients Resistant to anti-TNF Agents
Will the Biosimilars Bubble Burst Even Before It Expands?
FDA Should Forge Ahead on Biosimilar Drug Reviews: A Rheumatologist's Opinion
Amgen-Harvard Pilgrim Enter Outcomes-Based Contract for Enbrel